comparemela.com
Home
Live Updates
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases : comparemela.com
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on...
Related Keywords
China
,
Japan
,
Ping Li
,
Jiangxi
,
Shanghai
,
United States
,
Hangzhou
,
Zhejiang
,
Jing Zhong
,
Hubei
,
America
,
Chinese
,
American
,
Amber Cai
,
Aleksandar Kibel
,
Jian Feng Zhou
,
Debra Charlesworth
,
Kevin Eggan
,
Brinda Balakrishnan
,
Felisa Feng
,
Jay Hou
,
Traci Mccarty
,
Head Of Research
,
Group Vice
,
Biomarin Pharmaceutical Inc
,
Nasdaq
,
Exchange Commission
,
Prnewswire Biomarin Pharmaceutical Inc
,
Early Development
,
Business Development At Biomarin
,
Marin Pharmaceutical
,
Skyline Therapeutics
,
Adeno Associated Virus
,
Skyline Therapeutic
,
Investigational New Drug Application
,
Latin America
,
Group Vice President
,
Business Development
,
Chief Scientific Officer
,
Dilated Cardiomyopathy
,
Quarterly Report
,
Biomarin Pharmaceutical
,
Curr Heart Fail
,
Treatment Strategies
,
Specific Dilated Cardiomyopathies
,
Scientific Statement From
,
American Heart Association
,
Orphanet Report Series
,
Rare Diseases
,
Yong He Ding
,
Genetic Determinant
,
Familial Dilated Cardiomyopathy
,
Genotype Targeted Therapeutic Strategy
,
Cardiac Diseases
,
Cardiac Risk
,
Cardiorenal Pathology
,
Cardiac Interventions
,
Medical Pharmaceuticals
,
Health Care Amp Hospitals
,
Biotechnology
,
Contracts
,
comparemela.com © 2020. All Rights Reserved.